Protagonist Therapeutics, Inc.

The momentum for this stock is not very good. Protagonist Therapeutics, Inc. has good growth characteristics. Protagonist Therapeutics, Inc. is not very popular among insiders. Protagonist Therapeutics, Inc. is a mediocre stock to choose.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the r...

News

Protagonist Therapeutics price target raised by $10 at H.C. Wainwright, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by Brokerages

Ticker Report Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given a consensus rating of "Buy" by the six research firms that are covering the firm, MarketBeat.com reports. Six analysts...\n more…

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Great Lakes Advisors LLC

Zolmax Great Lakes Advisors LLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 3.8% in the second quarter, according to the company in its most recent filing with the...\n more…

Great Lakes Advisors LLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Ticker Report Great Lakes Advisors LLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 3.8% in the 2nd quarter, according to its most recent filing with the Securities and...\n more…

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Truist Financial

Ticker Report Truist Financial began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX - Free Report) in a report published on Monday morning, MarketBeat reports. The firm issued a buy rating and a...\n more…

Truist Financial Initiates Coverage on Protagonist Therapeutics (NASDAQ:PTGX)

Zolmax Truist Financial started coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX - Free Report) in a research note published on Monday morning, Marketbeat reports. The brokerage issued a buy...\n more…